Molecular imaging in neuroendocrine tumors: Molecular uptake mechanisms and clinical results

https://doi.org/10.1016/j.critrevonc.2009.02.009Get rights and content

Abstract

Neuroendocrine tumors can originate almost everywhere in the body and consist of a great variety of subtypes. This paper focuses on molecular imaging methods using nuclear medicine techniques in neuroendocrine tumors, coupling molecular uptake mechanisms of radiotracers with clinical results. A non-systematic review is presented on receptor based and metabolic imaging methods. Receptor-based imaging covers the molecular backgrounds of somatostatin, vaso-intestinal peptide (VIP), bombesin and cholecystokinin (CCK) receptors and their link with nuclear imaging. Imaging methods based on specific metabolic properties include meta-iodo-benzylguanide (MIBG) and dimercapto-sulphuric acid (DMSA-V) scintigraphy as well as more modern positron emission tomography (PET)-based methods using radio-labeled analogues of amino acids, glucose, dihydroxyphenylalanine (DOPA), dopamine and tryptophan. Diagnostic sensitivities are presented for each imaging method and for each neuroendocrine tumor subtype. Finally, a Forest plot analysis of diagnostic performance is presented for each tumor type in order to provide a comprehensive overview for clinical use.

Introduction

Neuroendocrine tumors are unique and rare tumors originating from neuroendocrine cells. These neuroendocrine cells are postulated to arise from common precursor cells of the embryologic neural crest and are dispersed throughout the human body. Characteristic is a common phenotype consisting of the simultaneous expression of general protein markers of neuroendocrine cells and hormonal products specific to each cell type [1]. The main function of neuroendocrine cells is to regulate a large variety of body functions through paracrine action with dedicated amines and peptides, of which the “biogenic amines”, such as serotonin and catecholamines, are most prominent. In order to be able to synthesize these amines, neuroendocrine cells have the ability to take up and decarboxylate amine precursors (APUD; amine precursor uptake and decarboxylation). Other biogenic amines, substances such as adrenocorticotropic hormone, growth hormone, neuropeptide K, substance P, bradykinin, kallikrein and prostaglandins can also be secreted [2], [3]. Neuroendocrine tumors arise in nearly every organ but primary sites in gastrointestinal (56%) and bronchopulmonary (12%) tracts are most frequent [4].

Due to the slow growth of most neuroendocrine tumors and the long time span between the onset of symptoms, many patients present with metastases (Fig. 1). Even with advanced disease, patients may survive for many years. However, there are also subtypes, which behave more aggressively. The diagnosis is based on histology and can be considered when specific symptoms induced by tumor products are present, such as diarrhea or flushing. Apart from clinical symptoms, determination of tumor secretory products using biochemical assays can assist in obtaining a diagnosis.

A division based on the embryological origin of the organs in which neuroendocrine tumors arise has been made in the past. This division classifies these tumors as foregut, midgut and hindgut tumors. However, the recent World Health Organization (WHO) classification of the different subtypes of neuroendocrine tumors of gastro-intestinal and pancreatic origin is based on histopathologic characteristics consisting of cellular grading, primary tumor size, primary tumor localization, proliferation markers, degree of invasiveness and the production of biologically active substances. The main categories defined by this classification are the well differentiated endocrine tumors with a low grade of malignancy, well differentiated, more aggressive carcinomas, poorly differentiated endocrine carcinomas with a high grade of malignancy and a poor prognosis and finally mixed exocrine–endocrine tumors. In this WHO classification the term carcinoid is abandoned and replaced by neuroendocrine tumor [5].

Currently, there is a broad variety of treatment options for patients with neuroendocrine tumors. Surgery is the only curative option. When cure is not possible, palliative treatment aims to control symptoms, maintain local tumor control and prolong life. Palliative procedures include surgical debulking, correction of bowel obstruction, chemo-embolizations, or systemic treatment using interferon-α or somatostatin analogues [2]. Other treatment options are chemotherapy and radionuclide therapy. New targeted therapies such as anti-angiogenic therapies are currently being explored [4], [6], [7].

Accurate localization of tumor lesions can guide treatment decisions. In general, radiological techniques such as CT, ultrasound or MRI are applied in staging and restaging, but also nuclear medicine techniques, such as somatostatin receptor scintigraphy (SRS), have proven to be of great value. The presence of somatostatin receptors on many neuroendocrine tumors was the driving force that enabled the development of SRS. Besides receptors, the remarkable metabolic activity of specific biochemical pathways used in substance synthesis provides possibilities for molecular nuclear medicine imaging.

The unique characteristics of neuroendocrine tumors have led to the development of interesting new diagnostic methods for these tumors over the last years, both in receptor imaging and metabolic imaging. Especially the increase in positron emission tomography (PET) facilities allows developments of tracers for new molecular targets with a high-resolution method for imaging. In addition new insights in the genetic, biochemical and metabolic aspects of subtypes of the neuroendocrine tumor family have arisen over the last years. It is therefore important to understand the receptor and metabolic targets for neuroendocrine tumors, as the molecular mechanisms that drive tracer uptake, translate into images and determine the final clinical applicability.

The unique characteristics of neuroendocrine tumors are increasingly exploited to successfully enhance our imaging and therapeutical options for these tumors. Three directions can be seen in the development of new tracers for imaging use. The first uses tumor receptor expression, the second uses the metabolic properties and the last method uses antibodies.

Therefore, the purpose of this review is to describe the receptor and metabolic imaging methods of neuroendocrine tumors and translate the molecular uptake mechanisms into clinical parameters such as sensitivity and specificity. For this purpose, a review of current literature is presented, both for imaging methods and for tumor types.

Section snippets

Search strategy and selection criteria

For this non-systematic review, a Medline and PubMed search was performed. Due to the many subtypes of neuroendocrine tumor and imaging methods a multitude of different search terms was necessary. A detailed list is available on request. Only papers with an English abstract published over the last 10 years (1995) were included. Material from review articles also referring to older studies was evaluated and was used if relevant. Reference lists of individual papers were also analyzed for study

Nuclear imaging methods

The methods for nuclear imaging of neuroendocrine tumors can be divided in three main categories, namely tracers based on (a) the selective expression of different receptors, (b) metabolic properties of tumors and (c) tracers which exploit antigens expressed by the tumors. For each category, currently available tracers will be described and their clinical impact. A schematic overview of the uptake mechanisms of these tracers can be found in Fig. 2.

A general principle in nuclear medicine is that

Conclusion

Most receptor-based tracers have been developed for scintigraphic use, and changing to positron emitting labels (i.e. 18F, 64Cu, 68Ga) could make these tracers suitable for PET imaging. For SRS, different somatostatin analogues are investigated which are more stable and bind more receptor subtypes with a higher affinity.

Most neuroendocrine tumors share common metabolic pathways, such as the catecholamine and serotonin pathways. Different strategies in the development of tracers suitable to

Conflict of interest statement

There are no conflicts of interest.

Prof. Elisabeth GE de Vries, M.D., Ph.D., Medical Oncologist UMCG. She is Professor in Medical Oncology and head of the Department of Medical Oncology and coordinator of the “Northern Netherlands Oncology Center”. She was research fellow (1982–1983) at the Department of Medical Oncology, City of Hope National Medical Center, Duarte, CA, USA. She is involved in patient care, teaching and research. Her research lines are aiming at increasing sensitivity of tumors for anticancer drugs and she uses

References (113)

  • I. Virgolini et al.

    Comparative somatostatin receptor scintigraphy using in-111-DOTA-lanreotide and in-111-DOTA-Tyr3-octreotide versus F-18-FDG-PET for evaluation of somatostatin receptor-mediated radionuclide therapy

    Ann Oncol

    (2001)
  • P. Guitera-Rovel et al.

    Indium-111 octreotide scintigraphy of Merkel cell carcinomas and their metastases

    Ann Oncol

    (2001)
  • E. Bombardieri et al.

    Somatostatin receptor imaging of small cell lung cancer (SCLC) by means of 111In-DTPA octreotide scintigraphy

    Eur J Cancer

    (1995)
  • R. Chin et al.

    Whole body FDG-PET for the evaluation and staging of small cell lung cancer: a preliminary study

    Lung Cancer

    (2002)
  • J.C. Reubi

    Neuropeptide receptors in health and disease: the molecular basis for in vivo imaging

    J Nucl Med

    (1995)
  • L.L. Schnirer et al.

    Carcinoid—a comprehensive review

    Acta Oncol

    (2003)
  • G. Kloppel et al.

    Pathology and nomenclature of human gastrointestinal neuroendocrine (carcinoid) tumours and related lesions

    World J Surg

    (1996)
  • I.M. Modlin et al.

    A 5-decade analysis of 13,715 carcinoid tumours

    Cancer

    (2003)
  • E. Solcia et al.

    Histologic typing of endocrine tumours. WHO International Histological Classification of Tumours

    (2000)
  • U. Plockinger et al.

    Guidelines for the diagnosis and treatment of neuroendocrine gastrointestinal tumours. A consensus statement on behalf of the European Neuroendocrine Tumour Society (ENETS)

    Neuroendocrinology

    (2004)
  • L.J. Hofland et al.

    The pathophysiological consequences of somatostatin receptor internalization and resistance

    Endocr Rev

    (2003)
  • E.P. Krenning et al.

    Somatostatin receptor scintigraphy with [111In-DTPA-d-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients

    Eur J Nucl Med

    (1993)
  • M. Schottelius et al.

    First (18)F-labeled tracer suitable for routine clinical imaging of sst receptor-expressing tumours using positron emission tomography

    Clin Cancer Res

    (2004)
  • M. Ginj et al.

    Preclinical evaluation of new and highly potent analogues of octreotide for predictive imaging and targeted radiotherapy

    Clin Cancer Res

    (2005)
  • S. Fanti

    Evaluation of unusual neuroendocrine tumours by means of 68Ga-DOTA-NOC PET

    Biomed Pharmacother

    (2008)
  • M. Gabriel et al.

    69Ga-DOTA-Tyr3-Octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT

    J Nucl Med

    (2007)
  • V. Ambrosini et al.

    Comparison between 68Ga-DOTA-NOC and 18F-DOPA PET for the detection of gastro-entero-pancreatic and lung neuro-endocrine tumours

    Eur J Nucl Med Mol Imaging

    (2008)
  • J.C. Reubi

    Peptide receptors as molecular targets for cancer diagnosis and therapy

    Endocr Rev

    (2003)
  • M.L. Thakur et al.

    PET imaging of oncogene overexpression using 64Cu-vasoactive intestinal peptide (VIP) analog: comparison with 99mTc-VIP analog

    J Nucl Med

    (2004)
  • E. Seretis et al.

    Comparative study of serotonin and bombesin in adenocarcinomas and neuroendocrine tumours of the colon

    Ultrastruct Pathol

    (2001)
  • J.C. Reubi et al.

    Bombesin receptor subtypes in human cancers: detection with the universal radioligand (125)I-[d-TYR(6), beta-ALA(11), PHE(13), NLE(14)] bombesin(6–14)

    Clin Cancer Res

    (2002)
  • J.C. Reubi et al.

    Concomitant expression of several peptide receptors in neuroendocrine tumours: molecular basis for in vivo multireceptor tumour targeting

    Eur J Nucl Med Mol Imaging

    (2003)
  • M. Behe et al.

    Cholecystokinin-B (CCK-B)/gastrin receptor targeting peptides for staging and therapy of medullary thyroid cancer and other CCK-B receptor expressing malignancies

    Biopolymers

    (2002)
  • M. Körner et al.

    GLP-1 receptor expression in human tumors and human normal tissues: potential for in vivo targeting

    J Nucl Med

    (2007)
  • D. Wild et al.

    Glucacon-like peptide 1-receptor scans to localize occult insulinomas

    N Eng J Med

    (2008)
  • P. Soares-da-Silva et al.

    High- and low-affinity transport of l-leucine and l-DOPA by the hetero amino acid exchangers LAT1 and LAT2 in LLC-PK1 renal cells

    Am J Physiol Renal Physiol

    (2004)
  • J.D. Ericksson et al.

    Distinct pharmacological properties and distribution in neurons and endocrine cells of two isoforms of the human vesicular monoamine transporter

    Proc Natl Acad Sci USA

    (1996)
  • F. Verrey

    System L: heteromeric exchangers of large neutral amino acids involved in directional transport

    Pflugers Arch

    (2003)
  • G. Firnau et al.

    Metabolites of 6-[18F]fluoro-l-DOPA in human blood

    J Nucl Med

    (1988)
  • J.M. Hoffman et al.

    The effects of carbidopa administration on 6-[18F]fluoro-l-DOPA kinetics in positron emission tomography

    J Nucl Med

    (1992)
  • I.P. Kema et al.

    Correspondence

    J Clin Oncol

    (2008)
  • S. Hoegerle et al.

    Whole-body 18F dopa PET for detection of gastrointestinal carcinoid tumours

    Radiology

    (2001)
  • A. Becherer et al.

    Imaging of advanced neuroendocrine tumours with (18)F-FDOPA PET

    J Nucl Med

    (2004)
  • K.P. Koopmans et al.

    Improved staging of patients with carcinoid and islet cell tumors with 18F-dihydroxy-phenyl-alanine and 11C-5-hydroxy-tryptophan positron emission tomography

    J Clin Oncol

    (2008)
  • K.P. Koopmans et al.

    Carcinoid crisis after injection of 6-18F-fluorodihydroxyphenylalanine in a patient with metastatic carcinoid

    J Nucl Med

    (2005)
  • L. Kolby et al.

    Uptake of meta-iodobenzylguanidine in neuroendocrine tumours is mediated by vesicular monoamine transporters

    Br J Cancer

    (2003)
  • N. Furuta et al.

    Diagnosis of pheochromocytoma using [123I]-compared with [131I]-metaiodobenzylguanidine scintigraphy

    Int J Urol

    (1999)
  • M.P. Hiorns et al.

    Radiology of neuroblastoma in children

    Eur Radiol

    (2001)
  • D.S. Goldstein et al.

    Metabolic fate of the sympathoneural imaging agent 6-[18F]fluorodopamine in humans

    Clin Exp Hypertens

    (1997)
  • I. Ilias et al.

    Superiority of 6-[18F]-fluorodopamine positron emission tomography versus [131I]-metaiodobenzylguanidine scintigraphy in the localization of metastatic pheochromocytoma

    J Clin Endocrinol Metab

    (2003)
  • Cited by (131)

    View all citing articles on Scopus

    Prof. Elisabeth GE de Vries, M.D., Ph.D., Medical Oncologist UMCG. She is Professor in Medical Oncology and head of the Department of Medical Oncology and coordinator of the “Northern Netherlands Oncology Center”. She was research fellow (1982–1983) at the Department of Medical Oncology, City of Hope National Medical Center, Duarte, CA, USA. She is involved in patient care, teaching and research. Her research lines are aiming at increasing sensitivity of tumors for anticancer drugs and she uses imaging techniques to support neuroendocrine tumors and breast cancer research. Apart from laboratory studies she performs and coordinates clinical studies. She served as member of the Scientific Board of the Dutch Cancer Society, KWF Kankerbestrijding, 1993–2000, the last 2 years as chairperson. Currently she is vice-chair of the board of Dutch Cancer Society. In 2002 she was appointed as member of the Royal Dutch Academy of Arts and Sciences (KNAW). She serves as member of the Health Council of the Netherlands, and is as of 2008 the chairperson of the Medical Sciences committee of the KNAW.

    Klaas P. Koopmans, M.D., Ph.D. He received his M.D. in 2000. In 2003 he started his Ph.D. project in collaboration with Oliver C. Neels (Radiochemist, Ph.D.). This project ‘Metabolic characterization and localization of neuroendocrine tumors and their metastases using positron emission tomography’ was funded by the Dutch Cancer Society. Oliver Neels is currently fellow at the Peter MacCallum Cancer Centre, East Melbourne, Australia. Klaas Pieter Koopmans started his residency nuclear medicine in 2006 and is still involved in research projects concerning neuroendocrine tumors.

    This work was supported by project grant 2003-2936 from the Dutch Cancer Society.

    View full text